Log in

goodpods headphones icon

To access all our features

Open the Goodpods app
Close icon
IDEA Collider - IDEA Collider | Dan Skovronsky

IDEA Collider | Dan Skovronsky

05/24/21 • 49 min

IDEA Collider

Dan Skovronsky is the chief scientific officer of Eli Lilly and Company. He serves as senior vice president of science and technology and president of Lilly Research Laboratories. He also has responsibility for global business development. Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. At Lilly, Dan has held various roles, including vice president, tailored therapeutics; vice president, diabetes research; and most recently, senior vice president, clinical and product development. Dan completed his residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. from the Perelman School of Medicine, University of Pennsylvania, in 2001 and his Ph.D. in Neuroscience from University of Pennsylvania in 2000. Dan earned a Bachelor of Science in molecular biophysics and biochemistry from Yale University in 1994..

plus icon
bookmark

Dan Skovronsky is the chief scientific officer of Eli Lilly and Company. He serves as senior vice president of science and technology and president of Lilly Research Laboratories. He also has responsibility for global business development. Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. At Lilly, Dan has held various roles, including vice president, tailored therapeutics; vice president, diabetes research; and most recently, senior vice president, clinical and product development. Dan completed his residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. from the Perelman School of Medicine, University of Pennsylvania, in 2001 and his Ph.D. in Neuroscience from University of Pennsylvania in 2000. Dan earned a Bachelor of Science in molecular biophysics and biochemistry from Yale University in 1994..

Previous Episode

undefined - IDEA Collider | Pharma Book Club | Brian Christian

IDEA Collider | Pharma Book Club | Brian Christian

With so much at stake in the application of AI/ Machine Learning to pharma, biotech and medicine, this wonderful book touches on biases, systems of learning, and the choices we have to make to properly harness the power of what is possible.

Email mike at ideapharma.com to enter a lottery to win a copy of the hardcover book, closing date 26th February.

From the page at brianchristian.org: A jaw-dropping exploration of everything that goes wrong when we build AI systems and the movement to fix them. Today’s “machine-learning” systems, trained by data, are so effective that we’ve invited them to see and hear for us—and to make decisions on our behalf. But alarm bells are ringing. Recent years have seen an eruption of concern as the field of machine learning advances. When the systems we attempt to teach will not, in the end, do what we want or what we expect, ethical and potentially existential risks emerge. Researchers call this the alignment problem. Systems cull résumés until, years later, we discover that they have inherent gender biases. Algorithms decide bail and parole—and appear to assess Black and White defendants differently. We can no longer assume that our mortgage application, or even our medical tests, will be seen by human eyes. And as autonomous vehicles share our streets, we are increasingly putting our lives in their hands. The mathematical and computational models driving these changes range in complexity from something that can fit on a spreadsheet to a complex system that might credibly be called “artificial intelligence.” They are steadily replacing both human judgment and explicitly programmed software. In best-selling author Brian Christian’s riveting account, we meet the alignment problem’s “first-responders,” and learn their ambitious plan to solve it before our hands are completely off the wheel. In a masterful blend of history and on-the ground reporting, Christian traces the explosive growth in the field of machine learning and surveys its current, sprawling frontier. Readers encounter a discipline finding its legs amid exhilarating and sometimes terrifying progress. Whether they―and we―succeed or fail in solving the alignment problem will be a defining human story. The Alignment Problem offers an unflinching reckoning with humanity’s biases and blind spots, our own unstated assumptions and often contradictory goals. A dazzlingly interdisciplinary work, it takes a hard look not only at our technology but at our culture―and finds a story by turns harrowing and hopeful. Read more at: https://brianchristian.org/the-alignment-problem/

Next Episode

undefined - IDEA Collider | Susanne Schaffert, PhD

IDEA Collider | Susanne Schaffert, PhD

As President of Novartis Oncology, Susanne Schaffert is pursuing a bold strategy to reimagine the research, development and commercialization of innovative treatments that will help improve and extend the lives of people with cancer and related blood disorders.

Susanne has held positions of increasing seniority across a range of business areas during her career at Novartis, having first joined the company as a sales representative in Germany in 1995. The majority of her roles have been in oncology, where she has a passion for making a difference in the lives of patients.

Prior to her current position, she served as President of Advanced Accelerator Applications, a Novartis company focused on the development of products for targeted radioligand therapy and precision imaging. Today, she leads more than 10 000 employees in 85 countries working to transform cancer care across four distinct therapeutic platforms.

Susanne is a respected business leader and scientist who was featured in Fortune’s “Most Powerful Women International” list in both 2019 and 2020. She actively mentors women at Novartis and encourages them to seek leadership roles. Susanne has a background in science and holds a doctorate in organic chemistry from the University of Erlangen in Germany, but as a former ballet dancer, she is also passionate about the arts. This dual interest informs her leadership philosophy, which celebrates diversity of thought and ideas as one of the keys to bold innovation.

Susanne also holds leadership positions in the broader pharmaceutical industry. She serves on the board and executive committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and is vice chair of EFPIA’s Patient Access Committee.

Susanne on LinkedIn: https://www.linkedin.com/in/susanne-schaffert-830b7053

Episode Comments

Generate a badge

Get a badge for your website that links back to this episode

Select type & size
Open dropdown icon
share badge image

<a href="https://goodpods.com/podcasts/idea-collider-654841/idea-collider-dan-skovronsky-86052093"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to idea collider | dan skovronsky on goodpods" style="width: 225px" /> </a>

Copy